Gene · 4751
Papers2,227
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,227
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Preparation of hepatocellular carcinoma mRNA vaccines based on potential tumor targets and immunophenotypes. | Transl Cancer Res | 2024 | 38410201 | PubTator, text mining | PubMed |
| Prolonged overexpression of PLK4 leads to formation of centriole rosette clusters that are connected via canonical centrosome linker proteins. | Sci Rep | 2024 | 38388511 | PubTator, text mining | PubMed |
| The Impact of miR-155-5p on Myotube Differentiation: Elucidating Molecular Targets in Skeletal Muscle Disorders. | Int J Mol Sci | 2024 | 38339055 | PubTator, text mining | PubMed |
| Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms. | Sci Rep | 2024 | 38308077 | PubTator, text mining | PubMed |
| Alternative splicing and related RNA binding proteins in human health and disease. | Signal Transduct Target Ther | 2024 | 38302461 | PubTator, text mining | PubMed |
| Dual roles of CCDC102A in governing centrosome duplication and cohesion. | Cell Rep | 2024 | 38280197 | PubTator, text mining | PubMed |
| Identification of dysregulation of sphingolipids in retinoblastoma using liquid chromatography-mass spectrometry. | Exp Eye Res | 2024 | 38246332 | PubTator, text mining | PubMed |
| Simulated microgravity altered the gene expression profiles and inhibited the proliferation of Kupffer cells in the early phase by downregulating LMO2 and EZH2. | Life Sci Space Res (Amst) | 2024 | 38245345 | PubTator, text mining | PubMed |
| Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic. | EBioMedicine | 2024 | 38244292 | PubTator, text mining | PubMed |
| Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers. | Oncogene | 2024 | 38182898 | PubTator, text mining | PubMed |
| Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma. | Cell Metab | 2024 | 38113887 | PubTator, text mining | PubMed |
| Post-transcriptional regulation of BIRC5/survivin expression and induction of apoptosis in breast cancer cells by tristetraprolin. | RNA Biol | 2024 | 38111129 | PubTator, text mining | PubMed |
| USP43 impairs cisplatin sensitivity in epithelial ovarian cancer through HDAC2-dependent regulation of Wnt/β-catenin signaling pathway. | Apoptosis | 2024 | 38087046 | PubTator, text mining | PubMed |
| PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma. | Endocr Connect | 2024 | 37992487 | PubTator, text mining | PubMed |
| Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD-L1 in Cancer Therapy. | Adv Sci (Weinh) | 2024 | 37934012 | PubTator, text mining | PubMed |
| Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. | Mol Cancer Ther | 2024 | 37816504 | PubTator, text mining | PubMed |
| In-silico studies of 2-aminothiazole derivatives as anticancer agents by QSAR, molecular docking, MD simulation and MM-GBSA approaches. | J Biomol Struct Dyn | 2024 | 37811574 | PubTator, text mining | PubMed |
| WNT/β-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities. | Genes Dis | 2024 | 37692481 | PubTator, text mining | PubMed |
| Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer. | J Natl Cancer Inst | 2024 | 37676829 | PubTator, text mining | PubMed |
| [Expression and clinical significance of NEK2 and EMT related molecules in oral squamous cell carcinoma]. | Shanghai Kou Qiang Yi Xue | 2023 | 38494974 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4751/papers?page=7